FATE THERAPEUTICS INC Stock Split Ratio
FATE THERAPEUTICS INC (FATE) reported Stock Split Ratio of 15.40% for the 0-month period ending 2013-09-12, per its 10-Q filed 2013-11-13.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2015-03-12
- 2013-09-12: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 15.40%; Stockholders' Equity Note, Stock Split, Conversion Ratio 15.40%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|---|
| 2013-09-12 | 15.40% 10-Q · filed 2013-11-13 | 15.40% 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |